U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C35H41N5O5
Molecular Weight 611.7305
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIHYDROERGOCRISTINE

SMILES

CC(C)[C@@]5(NC(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(C)C1)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](CC8=CC=CC=C8)N6C5=O

InChI

InChIKey=DEQITUUQPICUMR-HJPBWRTMSA-N
InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1

HIDE SMILES / InChI

Description

Dihydroergocristine is an ergot alkaloid that has an partial agonist activity on dopaminergic and alpha-adrenergic receptors and antagonist activity on serotonin receptors. The drug was approved by FDA in combination with other alkaloids (dihydroergocornine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine mesylate salts) under the name Hydergine for the treatment of dimentia and cerebrovascular insufficiency.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of phentolamine, dihydroergocristine and isoxsuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats.
1975
The treatment of minocycline-induced brainstem vertigo by the combined administration of piracetam and ergotoxin.
1989
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.
1992
Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation.
2001 Jan
Effects of topical natural ergot alkaloids on intraocular pressure and aqueous humor dynamics in ocular normotensive rabbits.
2002 Feb
Spinal gabapentin and antinociception: mechanisms of action.
2003 Apr
Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma.
2005 Dec
[Milestones of cardiovascular therapy. IV. Reserpine].
2007
Identification and human pharmacokinetics of dihydroergotoxine metabolites in man: preliminary results.
2008 Jan
Inappropriate medication use and risk of falls--a prospective study in a large community-dwelling elderly cohort.
2009 Jul 23
High-performance liquid chromatographic determination of dihydroergocristine in a pharmaceutical formulation with fluorescence detection.
2010 Jan-Feb
Roles of adenosine and serotonin receptors on the antinociception of sildenafil in the spinal cord of rats.
2010 Nov
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dosage (in form of hydergine tablets containing dihydroergocornine, dihydroergocristine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine mesylate salts in an approximate weight ratio of 1:1:1) in the US is 1 mg three times daily. In Europe and Japan, up to 12 mg of hydergine daily have been used without serious adverse effects.
Route of Administration: Oral
In Vitro Use Guide
C-1300 neuroblastoma cells were incubated with dihydroergocristine at concentration of 2 uM. In another experiment dihydroergocristine was added to the perfusion medium of the isolated rat brain in a concentration of 5 uM. In both experiments the drug caused changes in the concentrations of the high-energy phosphates.
Name Type Language
DIHYDROERGOCRISTINE
VANDF   WHO-DD  
Common Name English
GNF-PF-3462
Code English
DIHYDROERGOCRISTINE [VANDF]
Common Name English
DIHYDROERGOCRISTINE [WHO-DD]
Common Name English
EROTAMAN-3',6',18-TRIONE, 9,10-DIHYDRO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(PHENYLMETHYL)-, (5'ALPHA,10ALPHA)-
Common Name English
9,10-DIHYDROERGOCRISTINE
Common Name English
Classification Tree Code System Code
WHO-ATC C04AE04
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
WHO-VATC QC04AE04
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
WHO-VATC QC04AE54
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
WHO-ATC C04AE54
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
Code System Code Type Description
CAS
17479-19-5
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY
ChEMBL
CHEMBL601773
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY
PUBCHEM
107715
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY SWITZERF
WIKIPEDIA
Dihydroergocristine
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY
EVMPD
SUB13586MIG
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY
NCI_THESAURUS
C75938
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY
RXCUI
3416
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY RxNorm
EPA CompTox
17479-19-5
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY
ECHA (EC/EINECS)
241-493-4
Created by admin on Tue Mar 06 12:31:01 UTC 2018 , Edited by admin on Tue Mar 06 12:31:01 UTC 2018
PRIMARY